#trends today for 'fda grants' 'kristi noem' & 'severe storms'

Click/Tap below:

www.newsmason.com?query=%22fda...

www.newsmason.com?query=%22kri...

www.newsmason.com?query=%22sev...

#fdagrants #kristinoem #severestorms

#trends today for 'fda grants' 'ranbir kapoor' & 'child abuse'

Click/Tap below:

www.newsmason.com?query=%22fda...

www.newsmason.com?query=%22ran...

www.newsmason.com?query=%22chi...

#fdagrants #ranbirkapoor #childabuse

Maia Biotechnology stock soars after FDA grants Fast Track designation Investing.com -- Maia Biotechnology Inc (NYSE:MAIA) stock surged 11.2% in pre-market trading after the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its cancer treatment ateganosine. The designation was awarded for the treatment of non-small cell lung cancer (NSCLC), potentially accelerating the regulatory pathway for the drug. Ateganosine is currently being evaluated in a pivotal Phase 2 clinical trial measuring its anti-tumor activity when followed by a checkpoint inhibitor. Ateganosine works by compromising telomere structure and function in cancer cells, leading to tumor cell elimination and specific immune memory. Through its telomerase-mediated action, the drug is designed to reverse resistance to immune checkpoint inhibitors. "If we are successful in the Fast Track regulatory pathway, ateganosine could qualify for accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year," said MAIA Chairman and CEO Vlad Vitoc. The company reported that recent data from its Phase 2 THIO-101 clinical trial showed median overall survival of 17.8 months in a heavily pre-treated population, compared to 5 to 6 months typically seen with standard-of-care chemotherapy treatments in similar settings. NSCLC represents a significant market opportunity, valued at $34.1 billion in 2024 and projected to reach $68.8 billion by 2033 with an 8.1% CAGR. The FDA’s Fast Track program is designed to facilitate development and expedite review of drugs for serious conditions with unmet medical needs, potentially making the drug eligible for accelerated approval and priority review. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Before you buy stock in MAIA, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is MAIA one of them?

Click Subscribe #MaiaBiotechnology #StockMarket #FDAGrants #FastTrack #BiotechNews

Mustang Bio stock soars after FDA grants orphan drug designation Investing.com -- Mustang Bio Inc (NASDAQ:MBIO) stock surged over 78% after the U.S. Food and Drug Administration granted orphan drug designation to its MB-101 treatment for recurrent diffuse and anaplastic astrocytoma and glioblastoma, rare forms of brain cancer. The designation provides Mustang Bio with several benefits, including tax credits for clinical trials and seven years of market exclusivity if the treatment receives regulatory approval. The FDA’s designation covers a broader indication than what was originally proposed by the company. MB-101 consists of IL13Ra2-targeted CAR T-cells designed specifically to target these aggressive brain cancers. In an ongoing Phase 1 trial published in Nature Medicine, the treatment showed promising results with 50% of patients achieving stable disease or better outcomes. Notably, two patients achieved complete responses lasting 7.5 and 66+ months respectively. The study evaluated 57 patients total, with the two complete responses occurring in a cohort of three patients who had the highest levels of intratumoral CD3+ T cells before treatment. Mustang Bio is also developing MB-109, a combination therapy using MB-101 with MB-108, an oncolytic virus treatment for malignant glioma that previously received orphan drug designation. This combination approach uses MB-108 to modify the tumor microenvironment to potentially enhance MB-101’s effectiveness. The company noted that further development of the MB-109 program depends on securing additional funding or establishing a strategic partnership. Mustang licenses MB-101 from City of Hope and MB-108 from Nationwide Children’s Hospital. Phase 1 clinical trials for both treatments continue enrolling patients at City of Hope and The University of Alabama at Birmingham. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #MustangBio #StockMarket #FDAGrants #OrphanDrug #Investing